The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.

If you're too busy to keep monitoring your stock portfolio every other day, then investing in stocks that won't cause you a ...

Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...

Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...

It received FDA approval for weight loss in November 2023 under the brand name Zepbound. In the UK, the drug will be ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 500.39% and ...

A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn's disease, a new ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound ...

The Biden administration proposed expanding coverage of weight loss medication to Medicaid and Medicare recipients. RFK Jr.